中國生物科技服務(08037.HK)附屬公司與香港一家領先的醫療集團成立合營公司
格隆匯3月11日丨中國生物科技服務(08037.HK)宣佈,於2022年3月11日,公司間接控制60%權益的附屬公司華昇診斷中心有限公司("華昇診斷中心")與康健國際醫療集團有限公司("康健國際",連同其附屬公司,統稱為"康健國際集團")(一家其股份(股份代號:3886)在香港聯合交易所有限公司主板上市的公司)的全資附屬公司Sure Metro Limited("SML")訂立合營協議。
根據合營協議,華昇診斷中心及SML須分別認購香港醫學檢測中心有限公司("合營公司")的51股及48股股份("合營股份"),於簽署合營協議前,合營公司為SML的全資附屬公司。於合營協議完成後,華昇診斷中心及SML將會分別持有合營公司的51%及49%股權。
合營公司的業務將為在香港經營醫學實驗室("該實驗室"),以及為一般公眾客户提供(當中包括)COVID-19核酸檢測服務。
董事會認為,華昇診斷中心與康健國際集團成立合營公司將可把華昇診斷中心的COVID-19核酸檢測服務伸延至香港其中一個最大的私營醫療服務網絡。從長遠角度來看,預期華昇診斷中心與康健國際集團將會共同努力,將該實驗室發展成為香港一個能滿足其他常見醫療檢測服務需求的實驗室。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.